Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8738525 | 0.83 | MME (0.30) | MME | |
| SCHEMBL22236883 | 0.81 | — | — | |
| SCHEMBL25122099 | 0.78 | — | — | |
| SCHEMBL14883392 | 0.74 | TSHR (0.32) | MME | |
| SCHEMBL14883393 | 0.74 | TSHR (0.32) | MME | |
| SCHEMBL8737871 | 0.74 | CYP19A1 (0.37) | — | |
| SCHEMBL9609263 | 0.74 | TSHR (0.32) | MME | |
| SCHEMBL10281407 | 0.71 | TSHR (0.33) | MME | |
| SCHEMBL8102011 | 0.71 | HCAR2 (0.32) | — | |
| SCHEMBL23817365 | 0.69 | MME (0.33) | MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8900589-B2 | Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds | GENETECH, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-8389697-B2 | Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds | GENENTECH, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20120130059-A1 | ANTHRACYCLINE DERIVATIVE CONJUGATES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR COMPOUNDS | BERIA ITALO (IT) | 2012-05-24 | — | — | US | disclosed |
| US-20100034837-A1 | ANTHRACYCLINE DERIVATIVE CONJUGATES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR COMPOUNDS | GENENTECH, INC. | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100034837-A1 | ANTHRACYCLINE DERIVATIVE CONJUGATES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR COMPOUNDS | MRPL21, BCR, MYD88 | MME 1148/4885 |
| US-20120130059-A1 | ANTHRACYCLINE DERIVATIVE CONJUGATES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS ANTITUMOR COMPOUNDS | MRPL21, BCR, MYD88 | MME 1148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.